SMO and skin basal cell carcinoma: Sharpe HJ et al. also reported SMO mutations within (W281C, V321M, I408V, C469Y) and outside (T241M, A459V, L412F, S533N, and W535L are outside the drug-binding pocket, DBP) the DBP to be responsible for resistance in BCC patients [112].